UCB Raises 2025 Revenue Forecast, Citing Strong BIMZELX® Performance BRUSSELS – Global biopharmaceutical company UCB announced on Friday an upgraded financial forecast for 2025, raising its revenue expectation to exceed €7.6 billion. The company attributed the revision to robust year-to-date performance, led by the outperformance of its key growth drivers. The announcement was made from … Continue reading UCB Raises 2025 Revenue Forecast, Citing Strong BIMZELX Performance